Epilepsy is a chronic disease occurring in approximately
1.0% of the world’s population. About 30% of the epileptic patients treated
with available antiepileptic drugs (AEDs) continue to have seizures and are
considered therapy-resistant or refractory patients. The ultimate goal for the
use of AEDs is complete cessation of seizures without side effects. Because of
a narrow therapeutic index of AEDs, a complete understanding of its clinical
pharmacokinetics is essential for understanding of the pharmacodynamics of
these drugs. These drug concentrations in biological fluids serve as surrogate
markers and can be used to guide or target drug dosing. Because early studies
demonstrated clinical and/or electroencephalographic correlations with serum
concentrations of several AEDs, it has been almost 50 years since clinicians
started using plasma concentrations of AEDs to optimize pharmacotherapy in
patients with epilepsy. Therefore, validated analytical method for
concentrations of AEDs in biological fluids is a necessity in order to explore
pharmacokinetics, bioequivalence and Therapeutic Drug Monitoring (TDM) in
various clinical situations. There are hundreds of published articles on the
analysis of specific AEDs by a wide variety of analytical methods in biological
samples have appears over the past decade. This review intends to provide an
updated, concise overview on the modern method development for monitoring AEDs
for pharmacokinetic studies, bioequivalence and therapeutic drug monitoring.
Author(s) Details
Professor Ju-Seop Kang, Author(s) Details
Department of Pharmacology and Clinical Pharmacology Laboratory, College of Medicine, Hanyang University, Seoul 133-791,
View Book :- http://bp.bookpi.org/index.php/bpi/catalog/book/195
No comments:
Post a Comment